Biotechnology

KHB released FY2026 Q1 earnings on April 27 During-Market (BJT), actual revenue CNY 395.1 M, actual EPS CNY -0.0942

KHB to Release FY2026 Q1 Earnings on April 28 During-Market (BJT)

KHB released FY2025 Q4 earnings on April 16 After-Market BJT, actual revenue CNY 451.23 M, actual EPS CNY -0.9714

KHB released FY2025 Annual Earnings on April 16 After-Market BJT, actual revenue CNY 1.642 B, actual EPS CNY -1.4235

KHB to Release FY2025 Earnings Report on April 17 After-Market (BJT)

KHB released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 397.69 M, actual EPS CNY -0.1925

KHB released FY2025 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 1.191 B, actual EPS CNY -0.452

KHB to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

KHB released FY2025 Q2 earnings on August 26 Pre-Market (BJT), actual revenue CNY 405.69 M, actual EPS CNY -0.1558

KHB released FY2025 Semi-Annual Earnings on August 26 Pre-Market (BJT), actual revenue CNY 793.57 M, actual EPS CNY -0.2595

KHB to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Kehua Bioelectronics Wholly Subsidiary Establishes ShenZhen Kehua Huijian Technology

Kelhua Biotech Expected Net Loss of 120-170 Million in H1 2025

Kehua Biotech Responds to Research Directions and Mass Spectrometry Systems

Investor Questions Executability of Kelhua Biological's Valuation Improvement Plan

Company Responds to Investor Questions on Business Strategies and Future Plans

Kehua Bio-Engineering Reports Widening Net Loss in Q1 2025

KHB released FY2025 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 387.88 M, actual EPS CNY -0.1036

KHB released FY2024 Q4 earnings on April 27 After-Market BJT, actual revenue CNY 408.97 M, actual EPS CNY -1.0344

KHB released FY2024 Annual Earnings on April 27 After-Market (BJT), actual revenue CNY 1.759 B, actual EPS CNY -1.2687

002022

KHB (002022) won the bid for the procurement project of Tangshan Central Blood Station, with an amount of 1.1827 million yuan. The operating revenue for 2024 is 1.759 billion yuan, with a net profit of -641 million yuan and a return on net assets of -17.02%. In the first half of 2025, the operating revenue is 794 million yuan, with a net profit of -133 million yuan. The company's main products include genetic products and biological diagnostic reagents

同壁财经

KHB (002022): Won the procurement project of Tangshan Central Blood Station, with a bid amount of 1.1827 million yuan

36Kr learned that KHB stated on the interactive platform that its holding subsidiary Tianlong Company has an overall solution for Nipah virus testing, which can support key prevention and control nodes such as customs and disease control centers

36Kr

KHB: The holding subsidiary Tianlong Company has a comprehensive solution for Nipah virus testing

688317

301080

300639

300482

688399

688298

002030

300463

The A-share biopharmaceutical sector continues to strengthen, with Maccura, Hybribio Biotech, and KHB hitting the daily limit up in the afternoon. LIFERIVER and DAJY had previously reached their limit up, while WONDFO BIOTECH, ACROBIOSYSTEMS, Orient Biotech, and SSSW rose over 10%

Wallstreetcn

LIFERIVER

ACROBIOSYSTEMS

Hybribio Biotech

WONDFO BIOTECH

SSSW

Orient Biotech

DAJY

maccura

KHB announced that its revenue for the third quarter was 398 million yuan, a year-on-year decrease of 9.96%; the net profit loss was 99.0801 million yuan, a decrease of 42.20%. The revenue for the first three quarters was 1.191 billion yuan, a year-on-year decrease of 11.77%; the net profit loss was 233 million yuan, a decrease of 90.38%

Zhitong

KHB: Net profit loss of 99.0801 million yuan in the third quarter, a decrease of 42.20%

According to the Zhitong Finance APP, KHB announced that the company recently received a medical device registration certificate (in vitro diagnostic reagents) issued by the Shanghai Municipal Drug Administration. The product involved is the ferritin assay kit (latex immunoturbidimetric method). This kit is used by medical institutions for the quantitative determination of ferritin (FER) levels in human serum and plasma samples. Clinically, it is mainly used for the auxiliary diagnosis of iron metabolism-related diseases, such as hemochromatosis and iron deficiency anemia

KHB's product has obtained a medical device registration certificate

Shanghai KHB Biotechnology Co., Ltd. announced the repurchase results of the "KHB Convertible Bonds." The repurchase declaration period is from September 10, 2025, to September 16, 2025, with a repurchase price of 100.241 yuan per bond. The number of valid declarations is 70 bonds, with a total repurchase amount of 7,016.87 yuan. The funds will be credited on September 19, and allocated on September 22, with investors receiving the payment on September 23. This repurchase has no significant impact on the company's finances, and the unrepurchased "KHB Convertible Bonds" will continue to be traded on the Shenzhen Stock Exchange

KHB convertible bond repurchase results announced, 70 bonds repurchased for a total amount of 7,016.87 yuan

According to the Qichacha APP, recently, Jiangsu Tianlong Medical Technology Co., Ltd. was established, with Liang Jiaming as the legal representative and a registered capital of 10 million yuan. The business scope includes: operation of Class III medical devices; sales of Class II and III radiation devices; software outsourcing services; development of basic artificial intelligence software; sales of bio-based materials, etc. Qichacha's equity penetration shows that the company is jointly held by KHB Holdings Company Xi'an Tianlong Technology Co., Ltd. and Hainan Yikang Medical Technology Co., Ltd

KHB and others established a medical technology company, including the sales business of bio-based materials

According to the Zhitong Finance APP, KHB released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 794 million yuan, a year-on-year decrease of 12.65%. The net loss attributable to shareholders of the listed company was 133 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 140 million yuan, with a basic loss per share of 0.2595 yuan

KHB released its performance for the first half of the year, with a net loss attributable to the parent company of 133 million yuan

KHB stated on the interactive platform that there are currently no pesticide residue detection products for fruits, vegetables, and poultry. Its subsidiary, Tianlong Company, provides food safety-related testing products, including tests for foodborne pathogens such as African swine fever virus, Staphylococcus aureus, and Escherichia coli. In addition, Tianlong's handheld ATP fluorescence detector can quickly measure ATP levels in the environment and on surfaces, widely used in the food processing and catering industries to monitor cleaning and disinfection effectiveness, reducing the risk of cross-contamination

KHB: The company currently has no products for testing pesticide residues in fruits, vegetables, and poultry

KHB announced on the evening of August 11 that the company recently received a medical device registration certificate issued by the Shanghai Municipal Medical Products Administration. The product name is C-Reactive Protein Assay Kit. This kit is used by medical institutions for the in vitro quantitative determination of C-reactive protein levels in human serum and plasma samples, and is clinically used for the auxiliary diagnosis of non-specific inflammation

KHB: The company's products have obtained medical device registration certificates

KHB(002022.SZ)